2-Hydroxybenzylamine (2-HOBA) to Prevent Early Recurrence of Atrial Fibrillation After Catheter-based Ablation

Atrial Fibrillation Clinical Trial

Official title:

2-Hydroxybenzylamine (2-HOBA) to Prevent Early Recurrence of Atrial Fibrillation After Catheter- Based Ablation

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT04433091
• Other study ID #: 192520
• Status: Active, not recruiting
• Phase: Phase 2
• Start date: May 15, 2020
• Est. completion date: June 16, 2024

Study information

• Verified date: March 2024
• Source: Vanderbilt University Medical Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The proposed studies will test this hypothesis by randomizing patients with AF to 2-HOBA or placebo 7 days prior to AF ablation to allow 2-HOBA to reach steady-state levels. We hypothesize that tissue injury from AF ablation causes a large release of ROS that react with lipids to generate IsoLGs (Figure 2). In the absence of 2-HOBA, IsoLGs will react within seconds to form IsoLG-macromolecule adducts in atrial tissue, promoting early recurrence of AF. In the presence of 2-HOBA, IsoLGs will rapidly react to form IsoLG-macromolecule adducts in atrial tissue, promoting early recurrence of AF. In the presence of 2-HOBA, IsoLG will preferentially bind to and therefore be inactivated by 2-HOBA thereby sparing injury to the atrial tissue caused by oxidative stress and its contribution to early recurrence of AF. Early recurrence of AF will be measured by ECGs that are recorded once per day by a smartwatch (Apple Watch, Apple Inc., Cupertino, CA) with additional ECGs recorded by the participant if they experience symptoms of AF, or if the smartwatch alerts the participant of a possible AF episode via its auto-detection AF monitoring algorithm. The Apple Watch's AF algorithm is based on sampling of heart rate and variability and will give an audible alarm if those parameters indicate a possible episode of AF. The smartwatch records a single-lead ECG if the participant touches the watch with their contralateral hand. The day and time of the episode is also stored by the smartwatch. At the end of the 28-day follow-up period, study personnel will review the stored ECGs. Blood will be drawn prior to ablation and on post-procedure Day 1 for measurement of IsoLG-adduct levels. DNA will be extracted to explore a pharmacogenomic interaction with haplotypes at the chromosome 4q25 AF risk locus, which: 1) is strongly associated with the development of AF and the early recurrence of AF after ablation27; and 2) has been reported to be a regulator of an anti-oxidant gene program in response to cardiac injury.

Description:

The proposed double-blind, randomized, placebo-controlled trial of 2-HOBA in patients undergoing AF ablation is designed to address the following Specific Aims:

Specific Aim 1: To test the hypothesis that treatment with 2-HOBA reduces early recurrence of AF (clinical endpoint)

Specific Aim 2: To test the hypothesis that treatment with 2-HOBA reduces circulating levels of IsoLG-adducts (biochemical endpoint)

Specific Aim 3: To explore the idea that genetic variation at the 4q25 (PITX2) AF susceptibility locus modulates the clinical and biochemical response to 2-HOBA

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 99
• Est. completion date: June 16, 2024
• Est. primary completion date: June 16, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 22 Years and older

Eligibility

Inclusion Criteria:

• First time AF ablation with radiofrequency or cryo ablation

• Repeat AF ablation if the patient has persistent AF and ablation of non-pulmonary vein substrate is planned (e.g. posterior wall ablation, mitral or roof line, etc)

• Able to provide written, informed consent

• 22 years of age or older

Exclusion Criteria:

• Planned surgical or hybrid (surgical + catheter) ablation

• Amiodarone within past 3 months

• Use of oral steroids or colchicine

• Pro-inflammatory, rheumatologic disorder (e.g. RA, SLE, IBD, psoriasis, ankylosing spondylitis)

• NYHA Class III/IV Heart Failure

• LVEF <35%

• Active ischemia

• Hypertrophic Cardiomyopathy

• Cardiac or thoracic surgery within 6 months

• Expected life span < 1 year

• Creatinine clearance <30 ml/min

• Prior or planned heart transplantation

• Pregnant women

• Aspirin allergy

• Current use of MAO-I

Related Conditions & MeSH terms

• Atrial Fibrillation
• Recurrence

Intervention

Drug:
• 2-Hydroxybenzylamine
2-HOBA (2-Hydroxybenzlamine) 750mg will be given TID seven days prior to ablation and 28 days post ablation.

Other:
• Placebo
Placebo will be given TID for seven days prior to ablation and 28 days post ablation.

Locations

Country	Name	City	State
United States	Vanderbilt University Medical	Nashville	Tennessee

Sponsors (2)

Lead Sponsor	Collaborator
Vanderbilt University Medical Center	American Heart Association

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	An interaction will exist between the 4q25 GRS and the treatment group for an association with the early recurrence of AF.	DNA will be extracted and genotyping will be performed on a GWAS chip that includes the 3 SNPs located at chromosome 5125 that are independently associated with AF risk.	Pre-ablation.
Primary	2-HOBA reduces the rate of early recurrence of AF, atrial tachycardia, or atrial flutter following AF ablation within 28 days follow-up	Participants will wear a smartwatch linked to an iPhone to continually record heart rate, variability and detection of arrhythmias.; Participants will record a daily ECG each morning upon waking via the watch. In addition, participants will be notified by the smartwatch of 1) detection of atrial fibrillation or atrial flutter, 2) persistent high HR (> 110 bpm) outside of exercise	Post-ablation for 28 days
Primary	A secondary analysis will analyze a surrogate of AF burden as the endpoint and designed to account for the impact of cardioversion on AF burden assessment	A continuous heart rate monitor is provided by the smartwatch.which will be assessed by the AF burden and whether or not a cardioversion was performed.	Post-ablation for 28 days
Secondary	2-HOBA reduces the change in IsoLG-adduct levels that occurs with AF ablation.	AF ablation results in a significant increase in circulating IsoLG-adduct levels.	Pre-ablation and Post-procedure day #1